

1 **Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab** 2 **for Preventing Hospitalization and Mortality in COVID-19 Outpatients**

3 Neil R. Aggarwal, MD, MHSc^{a*}; Laurel E. Beaty, MS^{b*}; Tellen D. Bennett, MD, MS^{c,e}; Nichole
4 E. Carlson, PhD, MS^{b,e}; Christopher B. Davis, MD^d; Bethany M. Kwan, PhD, MSPH^{d,e,f}; David
5 A. Mayer, BS^b; Toan C. Ong, PhD^c; Seth Russell, MS^c; Jeffrey Steele, RN^g; Adane F. Wogu,
6 PhD^b; Matthew K. Wynia, MD, MPH^{a,h,i}; Richard D. Zane, MD^d; Adit A. Ginde, MD, MPH^{d,e}

7 ^a Department of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA

8 ^b Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045,
9 USA

10 ^c Section of Informatics and Data Science, Department of Pediatrics, University of Colorado
11 School of Medicine, Aurora, 80045, USA

12 ^d Department of Emergency Medicine, University of Colorado School of Medicine, Aurora,
13 80045, USA

14 ^e Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz
15 Medical Campus, Aurora, 80045, USA

16 ^f Department of Family Medicine, University of Colorado School of Medicine, Aurora, 80045,
17 USA

18 ^g Research Informatics, Children's Hospital Colorado, Aurora, 80045, USA

19 ^h Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus,
20 Aurora, 80045, USA

21 ⁱ Department of Health Systems Management and Policy, Colorado School of Public Health,
22 Aurora, 80045, USA

23 * Contributed equally to this manuscript

24 See Supplement for a full list of Contributors.

25

26 **Corresponding author:**

27 Neil R. Aggarwal, MD, MHSc

28 Department of Medicine

29 University of Colorado School of Medicine

30 12700 E. 19th Ave, Mail Stop C-272

31 Aurora, CO 80045, USA

32 Phone: +1-303-724-6038

33 Email: neil.aggarwal@cuanschutz.edu

34

35 **Running title:** Sotrovimab for COVID-19 Outpatients

36 **Word counts:** Abstract: 199, Manuscript text: 2944

37

38

39 **ABSTRACT**

40 **Background:** It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb)
41 treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-
42 CoV-2 Delta variant to prevent progression to severe disease and mortality.

43 **Methods:** Observational cohort study of non-hospitalized adult patients with SARS-CoV-2
44 infection from October 1st 2021 - December 11th 2021, using electronic health records from a
45 statewide health system plus state-level vaccine and mortality data. We used propensity
46 matching to select 3 patients not receiving mAbs for each patient who received outpatient
47 sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes
48 included mortality and severity of hospitalization.

49 **Results:** Of 10,036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were
50 matched to 1,563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab
51 treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate
52 2.1% versus 5.7%; adjusted OR 0.37, 95% CI 0.19-0.66) and an 89% decrease in the odds of all-
53 cause 28-day mortality (raw rate 0% versus 1.0%; adjusted OR 0.11, 95% CI 0.0-0.79), and may
54 reduce respiratory disease severity among those hospitalized.

55 **Conclusion:** Real-world evidence demonstrated sotrovimab effectiveness in reducing
56 hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta
57 variant phase.

58

59 **Keywords:** real-world evidence, COVID-19, sotrovimab, outpatients, mortality

60

61 **BACKGROUND**

62 High rates of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
63 the virus that causes coronavirus disease of 2019 (COVID-19), persist, especially among
64 unvaccinated individuals or those with waning vaccine or infection-related immunity.[1]
65 Neutralizing monoclonal antibody (mAb) treatment provides immediate passive immunity
66 against SARS-CoV-2. Several mAb products have received emergency use authorization (EUA)
67 from the US Food and Drug Administration[2] based on Phase II/III randomized clinical trials
68 conducted earlier in the pandemic that demonstrated efficacy towards reduced hospitalization
69 and disease severity among high-risk outpatients.[3-5] Use of mAb products such as sotrovimab
70 for individuals who have recently tested positive for SARS-CoV-2 in the outpatient setting is
71 critical to mitigate virus-driven impact on the health care system and is also an evidence-based
72 treatment strategy to improve COVID-19 outcomes among high-risk individuals.

73 Trials supporting mAb EUA approval were conducted prior to the emergence of the Delta
74 variant surge in the summer 2021, and the trial assessing sotrovimab efficacy was limited in
75 assessment of clinical outcomes or mortality.[4] Following EUA, however, it becomes more
76 challenging to recruit patients into randomized controlled trials.[6] As new variants such as Delta
77 and Omicron emerge, analysis of real-world data sufficiently robust to evaluate important
78 clinical differences is critical to evaluate treatment effectiveness and inform policy and practice
79 decisions. We previously used a real-world platform to report on mAb efficacy during the Delta
80 variant pandemic phase.[7] That prior report focused on mAbs administered through September
81 2021, predominantly consisting of casivirivimab plus imdevimab (~80%), bamlanivimab (~15%),
82 or bamlanivimab plus etesevimab (~3%). Sotrovimab had been administered to only 0.7% of the
83 overall cohort of patients with the Delta variant. Yet, as of January 24th, 2022, sotrovimab is the

84 only still-authorized mAb for outpatient COVID-19 treatment,[8] and thus additional data on its
85 clinical effectiveness is warranted.

86 To provide useful data to help inform mAb allocation strategies and related
87 policymaking, we leveraged our novel real-world evidence platform[7, 9, 10] to assess the
88 clinical impact of sotrovimab therapy on high-risk outpatients with early symptomatic COVID-
89 19 infections during a SARS-CoV-2 Delta predominant period in Colorado (10/1/2021 –
90 12/11/2021).[11] This paper reports on the effectiveness of sotrovimab against progression of
91 COVID-19 to severe disease, hospitalization, severity of hospitalization, and death.

92

93 **METHODS**

94 *Study Oversight and Data Sources*

95 We conducted a propensity-matched observational cohort study, as part of a statewide
96 implementation/effectiveness pragmatic trial, in a collaboration between University of Colorado
97 researchers, University of Colorado Health (UCHealth) leaders, and the Colorado Department of
98 Public Health and Environment (CDPHE). The study was approved by the Colorado Multiple
99 Institutional Review Board with a waiver of informed consent. We obtained data from the
100 electronic health record (EHR; Epic, Verona, WI) of UCHealth, the largest health system in
101 Colorado with 13 hospitals around the state and 141,000 annual hospital admissions, using
102 Health Data Compass, an enterprise-wide data warehouse. EHR data were merged with statewide
103 data on vaccination status from the Colorado Comprehensive Immunization Information System
104 and mortality from Colorado Vital Records.

105 *Patient Population Studied*

106 We included patients diagnosed with SARS-CoV-2 infection between October 1, 2021 and
107 December 11, 2021 allowing for at least 28 days of follow-up (n=10,036) (**Appendix Figure 1,**

108 **Supplement**). Patients were identified using an EHR-based date of SARS-CoV-2 positive test
109 (by polymerase chain reaction or antigen) or date of administration of mAb treatment (if no
110 SARS-CoV-2 test result date available). The decision to seek mAb treatment was made by
111 patients and clinicians.[11] We did not exclude patients solely for lack of EUA eligibility based
112 on EHR data, because not all eligibility criteria were consistently available in the EHR. We
113 excluded patients who tested positive for SARS-CoV-2 on the same day of or during
114 hospitalization because they were not eligible for mAb treatment. We also excluded patients
115 missing both a positive test date and a sotrovimab administration date (n=708), or if it had been
116 more than 10 days between the positive test date and sotrovimab administration (n=26), resulting
117 in a cohort of sotrovimab (N = 566) or mAb untreated (N = 9,470) patients.

118 Nearest neighbor propensity matching was conducted using logistic regression with
119 treatment status as the outcome. Approximately three untreated patients (N=1,563) were matched
120 to each sotrovimab-treated patient (N=522).[12, 13] Only 42 sotrovimab treated patients were
121 lost due to incomplete covariate data. The propensity model included categorical age, sex,
122 race/ethnicity, obesity status, immunocompromised status, number of comorbid conditions other
123 than obesity and immunocompromised status, number of vaccinations at time of infection, and
124 insurance status. We assessed effectiveness of matching using standardized mean differences
125 (SMDs) with a threshold of 0.1 with results shown in Appendix Table 2.[14]

126

127 ***Outcomes***

128 The primary outcome was all-cause hospitalization within 28 days of a positive SARS-CoV-2
129 test, obtained from EHR data. Secondary outcomes included 28-day all-cause mortality,
130 emergency department (ED) visit within 28 days, in-hospital disease severity based on maximum
131 level of respiratory support, hospital and intensive care unit (ICU) lengths of stay (LOS) in

132 survivors, rates of ICU admission, and in-hospital mortality. For both hospitalization and ED
133 visits, the index visit was used. When mAb treated patients were missing a SARS-CoV-2
134 positive date (70.5%), we randomly imputed missing test dates from the distribution of observed
135 time between SARS-CoV-2 to mAb administration.

136

137 *Variable Definitions*

138 Hospitalization was defined as any inpatient or observation encounter documented in the
139 EHR. ED visits were defined as any visit to the ED, with or without an associated inpatient or
140 observation encounter. Presence of comorbid conditions and immunocompromised status were
141 determined as reported previously[7] and described further in the Supplement. The number of
142 comorbid conditions was calculated as the sum of the presence of hypertension, cardiovascular
143 disease, diabetes, pulmonary disease, and renal disease.

144 COVID-19 disease severity was estimated using ordinal categories of respiratory support
145 requirements at an encounter level, based on the highest level of support received among the
146 following types (in increasing order): no supplemental oxygen, standard (nasal cannula/face
147 mask) oxygen, high-flow nasal cannula or non-invasive ventilation, and invasive mechanical
148 ventilation.[15] In-hospital mortality was the highest level of disease severity.

149 No virus sequencing results were available on an individual patient basis. However, this
150 analysis focused on a period when the Delta variant was dominant (>99% by state-wide data)[11]
151 and coupled with the timing of sotrovimab EUA and distribution in Colorado. Vaccination status
152 was categorized by the number of vaccinations (0, 1, 2, or ≥ 3) administered prior to the date of
153 the SARS-CoV-2 positive test.

154 The variables of interest include treatment status, categorical age in years, sex,
155 race/ethnicity, insurance status, obesity status, immunocompromised status, number of additional

156 comorbid conditions, and number of vaccinations. Due to small sample sizes, the variables age,
157 race/ethnicity, insurance status, number of comorbid conditions, and vaccination status were
158 each collapsed to the groups shown in the results tables.

159

160 *Statistical analysis*

161 Firth's logistic regression was used to assess the association between treatment and 28-day
162 hospitalization, 28-day mortality, and 28-day ED visits. Firth's logistic regression (R package
163 `logistf` V 1.24) addresses estimation issues related to low event rates and complete
164 separation.[16-18] All models were adjusted for age, sex, race/ethnicity, insurance status, obesity
165 status, immunocompromised status, number of additional comorbid conditions, and number of
166 vaccinations. The unadjusted number needed to treat (NNT) was calculated for hospitalization by
167 treatment status.

168 Due to the small number of hospitalized participants, descriptive statistics including
169 counts and raw rates were calculated for all secondary outcomes among hospitalized participants,
170 including disease severity, hospital LOS, ICU visit, and ICU LOS.

171 Kaplan-Meier curves were estimated to visually assess cumulative incidence patterns by
172 treatment status for 28-day hospitalization.

173 Two sensitivity analyses were performed. First, we repeated the above analysis using
174 only EUA-eligible patients as verified by available EHR data. Second, we repeated the above
175 analysis with a more conservative SARS-CoV-2 imputation approach where all missing positive
176 test dates were imputed as ten days prior to the mAb administration date (the maximum time
177 difference allowed by the EUA). All statistical analyses were performed using R Statistical
178 Software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria).[19]

179

180 **RESULTS**

181 *Characteristics of sotrovimab-Treated and mAb-Untreated Cohorts*

182 Of 10,036 patients with SARS-CoV-2 infection in the full cohort, 566 subjects received mAbs
183 and 9,470 patients did not (**Appendix Table 1, Supplement**). In the full cohort, the sotrovimab-
184 treated group generally reflects EUA criteria for use of mAbs, with many being older (33.0%
185 were age ≥ 65 years vs. 11.4% in mAb-untreated group), more likely to be obese (24.0% vs.
186 16.8%), or having one or more comorbidities (49.1% vs. 36.5%). Propensity matching eliminated
187 clinically meaningful differences in matching variables between groups (**Table 1, Appendix**
188 **Table 2, Supplement**). 522 sotrovimab-treated patients were propensity matched to 1,563
189 untreated patients.

190 The characteristics of sotrovimab-treated and mAb-untreated patients in the matched
191 cohort are presented (**Table 1**). The age distribution was similar, with 34% aged ≥ 65 . The cohort
192 was 56% female, 81% Non-Hispanic white, and 56% had private/commercial insurance.
193 Hypertension (32%) and pulmonary disease (25%) were the most common comorbid conditions.
194 Notably, 54% had received at least two vaccinations at the time of infection, and 39% had not
195 received any vaccine doses. The mean time from positive SARS-CoV-2 test to administration of
196 sotrovimab treatment was 3.7 days (SD 1.8) in those who did not have an imputed positive test
197 date.

198 *Hospitalization and Mortality*

199 Sotrovimab treatment was associated with a lower rate of 28-day hospitalization compared to
200 matched mAb-untreated controls (11 [2.1%] vs. 89 [5.7%]), representing a 63% decrease in the
201 adjusted odds of hospitalization (adjusted OR 0.37, 95% CI 0.19-0.68; $p < 0.001$) (**Table 2**). The
202 unadjusted NNT for hospitalization for the untreated group was 28. Based on a time-to-event
203 analysis, the benefits associated with reduced hospitalization were largely accrued within 12

204 days of the positive SARS-CoV-2 test date (**Figure 1**), or an average of 9 days after sotrovimab
205 treatment. Other factors associated with hospitalization are in Supplemental material (**Appendix**
206 **Table 3, Supplement**). Covariates that were associated with increased odds of 28-day
207 hospitalization included age ≥ 65 ($p = 0.049$), obesity ($p < 0.001$), and one ($p = 0.013$) or two or
208 more ($p < 0.001$) comorbid conditions other than obesity or immunocompromised status
209 (**Appendix Table 3, Supplement**). Each level of vaccination status (1, 2, or ≥ 3 doses) was
210 significantly associated with decreased odds of hospitalization in comparison to having no
211 vaccine.

212 Importantly, all-cause 28-day mortality in the sotrovimab-treated group was 0 (0%)
213 compared to 15 (1.0%) among the mAb-untreated group, equating to an 89% decrease in the
214 mortality odds (adjusted OR 0.11, 95% CI 0.0-0.79 (**Table 2**). There was not a significant
215 association between sotrovimab treatment and the odds of visiting the ED (adjusted OR 1.12,
216 95% CI 0.77-1.60).

217 *Severity of Hospitalization*

218 Among hospitalized patients, 0 of 11 (0%) in the sotrovimab-treated group required invasive
219 mechanical ventilation (IMV) or died in the hospital, compared to 19 of 89 (21.3%) mAb-
220 untreated group (**Table 2**). We also observed that a higher proportion of sotrovimab-treated
221 patients required no supplemental oxygen or only required standard (low-flow) oxygen in
222 comparison to mAb-untreated patients (72.7% vs. 48.3%). The average hospital length of stay
223 (LOS) for sotrovimab patients was 5.3 (+/- 5.9) days in comparison to 9.4 (+/- 10.6) days in the
224 untreated group. Collectively, these data suggest a lower severity of disease among hospitalized
225 sotrovimab-treated patients, although statistical inference was not performed (**Figure 2**). 2 of 9
226 (18.2%) sotrovimab-treated patients required ICU level of care, a similar percentage compared to
227 mAb-untreated patients (21.3%).

228 *Sensitivity Analysis*

229 Neither restricting the cohort to only patients meeting EUA eligibility criteria based on available
230 EHR data or using a more conservative imputation method for missing date of positive SARS-
231 CoV-2 test materially changed the key results and scientific conclusions (**Appendix Tables 4-7,**
232 **Supplement**).

233

234 **DISCUSSION**

235 During a SARS-CoV-2 Delta variant-predominant period in Colorado, sotrovimab reduced 28-
236 day hospitalization by 63% and all-cause 28-day mortality by 89%. Our study adds to the main
237 prior clinical trial demonstrating sotrovimab efficacy that had limited sample size (n=583),
238 occurred prior to the emergence of the Delta variant, and was underpowered to evaluate the
239 impact of sotrovimab on patient mortality.[4] This data on the effectiveness of sotrovimab to
240 prevent severe COVID-19 disease induced by the Delta variant may be critical given the
241 unpredictable nature of the COVID-19 pandemic. When combined with in vitro data that
242 suggests sotrovimab effectively neutralizes the omicron variant,[20] these data support continued
243 sotrovimab prioritization among outpatient treatment options.

244 Although we do not directly compare sotrovimab effectiveness to other mAbs used
245 during a Delta variant-dominated pandemic phase, it is notable that the adjusted OR for 28-day
246 hospitalization in our study (aOR 0.37) is similar to what we previously reported (aOR 0.48)
247 when casivirimab plus imdevimab, bamlanivimab, or bamlanivimab plus etesevimab use as
248 outpatient mAb therapy were far more common than sotrovimab.[7] Further supporting
249 sotrovimab effectiveness against the Delta variant of SARS-CoV-2 is a comparable NNT of 28
250 to prevent one hospitalization, which we observed despite both an increase in the overall

251 vaccination rate and a lower baseline hospitalization rate among mAb-untreated patients
252 compared to the earlier cohort.[7]

253 Our results are of practical importance for policymakers and clinicians because there
254 have been shortages of mAb supplies and infusion capacity, and as such, demonstrating their
255 effectiveness to reduce hospitalization and mortality against each clinically relevant SARS-CoV-
256 2 variant is crucial.[21, 22] Study findings support continued use of sotrovimab for patients with
257 high baseline risk for hospitalization, including those who are older than 65, obese, are not fully
258 vaccinated, or have comorbid conditions, all of whom had increased rates of hospitalization in
259 our cohort.

260 *Limitations*

261 This study has several limitations. The setting was a single health system and geographically
262 limited to one US state with relatively low racial and ethnic minority representation, though it
263 serves both urban and rural populations through academic and community hospitals. Even
264 though we used statewide data for mortality and vaccination status, hospitalizations were
265 collected only within one single health system. If mAb-untreated patients were less likely to be
266 seen in this health system, hence more likely to be hospitalized elsewhere, this may bias our
267 results toward the null. We also relied on EHR data, including manual chart reviews, which may
268 have missing or inaccurate information about the presence of chronic conditions.[23] These
269 factors might have limited our ability to detect the impact of sotrovimab treatment.

270 We only collected 28-day hospitalization and mortality data, and therefore we do not
271 know whether sotrovimab effectiveness extends to a longer period after SARS-CoV-2 infection.
272 However, our prior study would suggest that 28-day and 90-day data are similar with respect to
273 hospitalization and mortality endpoints.[7] In this study, propensity scoring achieved excellent
274 matching between mAb-treated and mAb-untreated patient groups across multiple variables, but

275 unmeasured confounders may remain. Our EHR data does not contain information on SARS-
276 CoV-2 variants at the patient level. However, during Colorado's Delta phase more than 99% of
277 sequenced SARS-CoV-2 was Delta variant.[11]

278 Finally, this study was conducted during a limited portion of the Delta variant-dominant
279 period after sotrovimab drug distribution and infusion had been well-established in Colorado. In
280 addition, hospitalization rates were lower over this same period, precluding our ability to
281 perform inferential statistics on severity of illness among the hospitalized sub-cohort. Because
282 the trend among the hospitalized subset strongly suggests sotrovimab benefit in reducing disease
283 severity and hospital length of stay, examining sotrovimab effectiveness across US states during
284 the same period would seemingly be an important next step to evaluate the generalizability of
285 our findings. With the rapid emergence of the Omicron variant in mid-December 2021, our intent
286 is to separately evaluate sotrovimab effectiveness against the omicron variant after enough
287 treated and untreated cases have accrued. The Omicron variant has an abundance of mutations in
288 the receptor-binding motif (RBM) of SARS-CoV-2, however in vitro reports suggest preserved
289 neutralization of Omicron by sotrovimab,[24] potentially explained by its ability to target non-
290 RBM epitopes shared across many sarbecoviruses, including SARS-CoV-1.

291 ***Conclusion***

292 This study demonstrated real-world evidence for effectiveness of sotrovimab treatment in
293 reducing hospitalizations among COVID-19 outpatients during the Delta variant phase, as well
294 as a remarkable 89% overall reduction in mortality at 28 days, compared to matched mAb-
295 untreated patients. For hospitalized patients, prior outpatient sotrovimab treatment may reduce
296 respiratory disease severity, hospital length of stay, and death, but a larger cohort is necessary to
297 further examine this observation. When access to mAbs is limited, prioritizing patients at highest

298 risk for hospitalization has the most potential to reduce health system strain during the COVID-
299 19 pandemic.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315 **FOOTNOTES**

316 1) The authors do not have a commercial or other association that might pose a conflict of
317 interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership,
318 relevant patents, or research funding)

319
320 2) This study was funded by the National Center for Advancing Translational Sciences of the
321 National Institutes of Health [grant numbers UL1TR002525, UL1TR002535-03S3 and
322 UL1TR002535-04S2].

323
324 3) This work has not been presented in part or in entirety at any meetings

325
326 4) Correspondence and reprints to:
327 Neil R. Aggarwal, MD, MHSc
328 Department of Medicine
329 University of Colorado School of Medicine
330 12700 E. 19th Ave, Mail Stop C-272
331 Aurora, CO 80045, USA
332 Phone: +1-303-724-6038
333 Email: neil.aggarwal@cuanschutz.edu

334
335
336
337
338

339 **REFERENCES**

- 340 1. Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 infection-
341 induced and vaccine-induced immunity. Available at:
342 [https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html)
343 [immunity.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html)). Accessed February 10.
- 344 2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
345 treatment guidelines. Available at: <https://www.covid19treatmentguidelines.nih.gov>.
346 Accessed February 10.
- 347 3. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or
348 Moderate Covid-19. *N Engl J Med* **2021**; 385(15): 1382-92.
- 349 4. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or
350 Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized
351 Clinical Trial. *JAMA* **2022**.
- 352 5. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing
353 Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* **2021**; 384(3): 238-51.
- 354 6. Lynch HF, Caplan A, Furlong P, Bateman-House A. Helpful Lessons and Cautionary
355 Tales: How Should COVID-19 Drug Development and Access Inform Approaches to
356 Non-Pandemic Diseases? *Am J Bioeth* **2021**; 21(12): 4-19.
- 357 7. Wynia MK, Beaty LE, Bennett TD, et al. Real World Evidence of Neutralizing
358 Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19
359 Outpatients. *medRxiv* **2022**.
- 360 8. Cavazzoni P, MD. Coronavirus (COVID-19) Update: FDA Limits Use of Certain
361 Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant. In:
362 Administration FD, **2022**.

- 363 9. ISPOR. About real-world evidence. December 2021. Available at:
364 [https://www.ispor.org/strategic-initiatives/real-world-evidence/about-real-world-
366 evidence](https://www.ispor.org/strategic-initiatives/real-world-evidence/about-real-world-
365 evidence).
- 366 10. Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic.
367 *JAMA* **2020**; 323(19): 1895-6.
- 368 11. Colorado Department of Public Health and Environment. Treatments for Covid-19.
369 Available at: [https://covid19.colorado.gov/for-coloradans/covid-19-treatments#collapse-
371 accordion-40911-4](https://covid19.colorado.gov/for-coloradans/covid-19-treatments#collapse-
370 accordion-40911-4). Accessed February 10.
- 371 12. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
372 Confounding in Observational Studies. *Multivariate Behav Res* **2011**; 46(3): 399-424.
- 373 13. Daniel Ho KI, Gary King, and Elizabeth Stuart. Matching as Nonparametric
374 Preprocessing for Reducing Model Dependence in Parametric Causal Inference. *Political
375 Analysis* **2007**; 15: 199-236.
- 376 14. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates
377 between treatment groups in propensity-score matched samples. *Stat Med* **2009**; 28(25):
378 3083-107.
- 379 15. National Institute of Health Covid treatment guidelines. Clinical spectrum of SARS-
380 CoV-2 infection. . Available at:
381 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum>.
382 Accessed **February 10**.
- 383 16. Georg Heinze MPaLJ. logistf: Firth's Bias-Reduced Logistic Regression. R package
384 version 1.24. **2020**.
- 385 17. Heinze G, Schemper M. A solution to the problem of separation in logistic regression.
386 *Stat Med* **2002**; 21(16): 2409-19.

- 387 18. Puhr R, Heinze G, Nold M, Lusa L, Geroldinger A. Firth's logistic regression with rare
388 events: accurate effect estimates and predictions? *Stat Med* **2017**; 36(14): 2302-17.
- 389 19. Team RC. R: a language and environment for statistical computing. Vienna: R
390 Foundation for Statistical Computing, **2020**.
- 391 20. Cameroni E, Saliba C, Bowen JE, et al. Broadly neutralizing antibodies overcome SARS-
392 CoV-2 Omicron antigenic shift. *bioRxiv* **2021**.
- 393 21. Strategies to allocate scarce COVID-19 monoclonal antibody treatments to eligible
394 patients examined in new rapid response to government. January 2021. Available at:
395 [https://www.nationalacademies.org/news/2021/01/strategies-to-allocate-scarce-covid-19-](https://www.nationalacademies.org/news/2021/01/strategies-to-allocate-scarce-covid-19-monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-government)
396 [monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-](https://www.nationalacademies.org/news/2021/01/strategies-to-allocate-scarce-covid-19-monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-government)
397 [government](https://www.nationalacademies.org/news/2021/01/strategies-to-allocate-scarce-covid-19-monoclonal-antibody-treatments-to-eligible-patients-examined-in-new-rapid-response-to-government)). Accessed February 10.
- 398 22. Bernstein L. Biden Administration moves to stave off shortages of monoclonal
399 antibodies. Accessed February 10.
- 400 23. Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and Prediction of
401 Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US
402 National COVID Cohort Collaborative. *JAMA Netw Open* **2021**; 4(7): e2116901.
- 403 24. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529
404 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*
405 **2022**.
- 406

407 **Table 1. Baseline Characteristics by Mab Treatment Status for Primary Matched Cohort**

Characteristic	Sotrovimab-Treated	mAb-Untreated
Age Group^a		
18-44 years	169 (32.4%)	486 (31.1%)
45-64 years	177 (33.9%)	537 (34.4%)
≥65 years	176 (33.7%)	540 (34.5%)
Sex^a		
Female	296 (56.7%)	877 (56.1%)
Race/Ethnicity^a		
Non-Hispanic White	421 (80.7%)	1271 (81.3%)
Hispanic	39 (7.5%)	118 (7.5%)
Non-Hispanic Black	21 (4.0%)	57 (3.6%)
Other	41 (7.9%)	117 (7.5%)
Insurance Status^a		
Private/Commercial	294 (56.3%)	876 (56.0%)
Medicare	175 (33.5%)	534 (34.2%)
Medicaid	34 (6.5%)	99 (6.3%)
None/Uninsured	13 (2.5%)	39 (2.5%)
Other/Unknown	6 (1.1%)	15 (1.0%)
Immunocompromised Status^a		
Yes	130 (24.9%)	347 (22.2%)
Obesity Status^a		
Yes	133 (25.5%)	394 (25.2%)
Number of Other Comorbid Conditions^a		
None	251 (48.1%)	767 (49.1%)
One	147 (28.2%)	421 (26.9%)
Two or more	124 (23.8%)	375 (24.0%)
Diabetes	62 (11.9%)	209 (13.4%)
Cardiovascular Disease	86 (16.5%)	242 (15.5%)
Pulmonary Disease	131 (25.1%)	390 (25.0%)
Renal Disease	32 (6.1%)	112 (7.2%)
Hypertension	160 (30.7%)	497 (31.8%)
Liver Disease	39 (7.5%)	114 (7.3%)
Number of vaccinations prior to SARS-		
CoV-2+ date^a		
0	200 (38.3%)	604 (38.6%)
1	37 (7.1%)	109 (7.0%)
2	233 (44.6%)	699 (44.7%)
≥3	52 (10.0%)	151 (9.7%)

408 ^a Variables used in the propensity matching. Abbreviations: mAb, monoclonal antibody

409

410 **Table 2. Primary and Secondary Outcomes by Monoclonal Antibody Treatment Status**

Outcome	Sotrovimab-Treated mAb-Untreated		Adjusted OR	95% CI
Overall Sample Size	N=522	N=1563		
All-Cause 28-day Hospitalization (<i>primary outcome</i>)	11 (2.1%)	89 (5.7%)	0.37	(0.19, 0.68)
All-Cause 28-day Mortality	0 (0.0%)	15 (1.0%)	0.11	(0.00, 0.79)
Any ED visit to Day 28	44 (8.4%)	119 (7.6%)	1.12	(0.77, 1.60)
Hospitalized Sample Size	N=11	N=89		
Hospital LOS days, mean (SD)	5.3 (5.9)	9.4 (10.6)	--	--
IMV or Death	0 (0.0%)	19 (21.3%)	--	--
ICU Admission	2 (18.2%)	19 (21.3%)	--	--
ICU LOS days, mean (SD)	5.5 (6.4)	8.6 (10.1)	--	--

411 All regression models adjusted for age, sex, race/ethnicity, obesity, immunocompromised status,
 412 number of comorbidities, insurance status, and vaccination status. Abbreviations: mAb,
 413 monoclonal antibody; OR, odds ratio; CI, confidence interval; ICU, intensive care unit; IMV,
 414 invasive mechanical ventilation; LOS, length of stay; SD, standard deviation

415
 416
 417
 418
 419

420 **FIGURE LEGENDS**

421 **Figure 1. Cumulative Incidence Plots for All-Cause Hospitalization to Day 28 by**

422 **Sotrovimab Treatment Status**

423 **Figure 2. Maximum Respiratory Support by Monoclonal Antibody Treatment Status**

424 **among Patients Hospitalized within 28 Days**

425 Comparing severity of hospitalizations for n=11 sotrovimab-treated and n=89 mAb-untreated
426 patients, the maximum level of respiratory support appeared lower for sotrovimab-treated
427 patients, but inferential statistics were not able to be performed.

428 Abbreviations: mAb, monoclonal antibody; HFNC, high-flow nasal cannula oxygen; NIV, non-
429 invasive ventilation; IMV, invasive mechanical ventilation

430 **Figure 1. Cumulative Incidence Plots for All-Cause Hospitalization to Day 28 by**
 431 **Sotrovimab Treatment Status**

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450


451

452

453

454

455



456 **Figure 2. Maximum Respiratory Support by Monoclonal Antibody Treatment Status**
457 **Among Patients Hospitalized within 28 Days**

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

